CD437 (AHPN)

CD437 (AHPN) is an agonist of Retinoid Receptors used in studies of Apoptosis and Hormone Signaling. It is especially relevant in apoptosis, cancer, and developmental biology models, where defined compound exposure can be linked to caspase-associated cell-death signaling and survival decisions and ligand-dependent transcriptional programs and endocrine regulation.

By activating Retinoid Receptors, CD437 (AHPN) can be used to examine caspase-associated cell-death signaling and survival decisions and ligand-dependent transcriptional programs and endocrine regulation. The nuclear receptor annotation adds relevance to reporter-gene, receptor-binding, and transcriptional assays, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and developmental biology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving Retinoid Receptors
• Pathway perturbation studies connected to Apoptosis and Hormone Signaling
• Agonist-response and downstream signaling studies
• Reporter-gene, receptor-binding, and transcriptional assays

Overall, CD437 (AHPN) is appropriate when a defined chemical perturbant is needed to connect Retinoid Receptors with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and developmental biology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.